---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-024156"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T12:09:19.923964+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics enters $947,000 at-the-market equity offering agreement with Ascendiant Capital

## Summary
- Company entered ATM sales agreement with Ascendiant Capital for up to $947,000 of common stock.
- Agent commission 3.0% of gross proceeds; expenses reimbursement up to $30,000.
- Sales may be made on Nasdaq at market prices; agreement effective until March 2026 or earlier termination.
- Placement Shares subject to General Instruction I.B.6 limitations until public float exceeds $75M.

## SEC filing metadata
- accession: 0001213900-24-024156
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024024156/0001213900-24-024156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024024156/ea0202127-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-024156
- JSON: https://secwatch.observer/filing/0001213900-24-024156.json
- Plain text: https://secwatch.observer/filing/0001213900-24-024156.txt

## Key facts
- Material Agreements
  Allarity Therapeutics, Inc. entered into At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $947,000 (effective 2024-03-19).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Ascendiant Capital Markets, LLC
  - Value: up to $947,000
  - Effective: 2024-03-19
  source text: On March 19, 2024, Allarity Therapeutics, Inc. (the “ Company ”), entered into an At-The-Market Issuance Sales Agreement (the “ Agreement ”) with Ascendiant Capital Markets, LLC (the “ Agent ”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024024156/0001213900-24-024156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.